Last reviewed · How we verify
Lenalidomide and Rituximab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Lenalidomide and Rituximab (Lenalidomide and Rituximab) — Chronic Lymphocytic Leukemia Research Consortium.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lenalidomide and Rituximab TARGET | Lenalidomide and Rituximab | Chronic Lymphocytic Leukemia Research Consortium | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lenalidomide and Rituximab CI watch — RSS
- Lenalidomide and Rituximab CI watch — Atom
- Lenalidomide and Rituximab CI watch — JSON
- Lenalidomide and Rituximab alone — RSS
Cite this brief
Drug Landscape (2026). Lenalidomide and Rituximab — Competitive Intelligence Brief. https://druglandscape.com/ci/lenalidomide-and-rituximab. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing